Abstract. the aim of this study was to detect the expression of the Forkhead box M1 (FoXM1) protein in human hepatocellular carcinoma (Hcc) and to associate FoXM1 expression with clinicopathological features of the patients, and predict the prognosis of patients with FoXM1 expression. surgical tissue specimens from 151 Hcc patients were subjected to a tissue microarray construction and immunohistochemistry analysis of FoXM1 and the proliferation marker proliferating cell nuclear antigen (pcnA). the data showed that the FoXM1 protein was expressed in 59.3% of the Hcc tissues, which was significantly higher compared to that of the surrounding non-tumorous tissues (23.8%; p<0.001). Moreover, FoXM1 expression was positively correlated with the labeling index of pcnA (p<0.001) in Hcc and with aggressive tumor phenotypes, such as larger tumor size, multiple tumors, bilobar involvement, poor tumor cell differentiation, advanced stage and macrovascular invasion (p<0.05). In addition, Hcc patients with FoXM1-positive tumors had a poorer recurrencefree and overall survival after hepatectomy than those with FoXM1-negative tumors. Multivariate cox regression analysis demonstrated that FoXM1 expression was an independent predictor of unfavorable outcome (p<0.05). the data from the current study suggest that FoXM1 may play an important role in Hcc progression and could be further evaluated as a prognostic biomarker and potential therapeutic target.
Introduction
Hepatocellular carcinoma (Hcc) is a major health concern with a high morbidity and mortality rate worldwide (1) . the incidence of Hcc continues to increase due to the prevalence of hepatitis B virus infection in Asian countries and increased hepatitis c virus infection in the Western world (1, 2) . For clinical management of Hcc, surgical resection is still the mainstay of curative modality to date. nevertheless, long-term survival of Hcc is mainly haunted by postoperative tumor recurrence (1, 3) . to increase the chances of applying timely treatment for Hcc patients, prediction of risk for individual recurrence and subsequent prognosis is of critical importance. It is believed that Hcc-associated genes, the intrinsic modulators of cancer biology, may hold considerable promise to accurately assess prognostic predictions of Hcc patients and provide for putative therapeutic targets (4, 5) . With our increasing understanding of molecular events involved in Hcc, interest has grown in exploring biological markers for their clinical application.
the evolutionarily conserved forkhead box (Fox) family genes of transcriptional regulators consist of more than 50 mammalian proteins that share homology in the winged helix DnA-binding domain (6) (7) (8) (9) (10) (11) . of the Fox members, Forkhead box M1 (FoXM1) protein shows some uniqueness, being abundantly expressed in the transformed cells and a variety of human cancers but undetectable in various differentiated cells and quiescent adult tissues (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . It has recently been shown that conditional deletion of FoXM1 expression in mouse hepatocytes resulted in failure in cell proliferation and resistance to liver tumor induction by diethylnitrosamine (Den)/phenobarbital (PB) (6) . Furthermore, either FOXM1 allele deficiency or inhibition of FoXM1 function diminished tumor growth and proliferation in mouse liver tumors (7). In addition, knockdown of FoXM1 by sirnA inhibited proliferation and invasion of human Hcc cells in vitro (8) . these data strongly suggest that FoXM1 plays a crucial role in hepatocarcinogenesis and tumor progression, which may support the notion that FoXM1 expression could be associated with malignant potential and unfavorable prognosis of Hcc. Follow-up of patients after surgery. the studied subjects were followed up for 17.8 months (ranged between 1.2-85 months). Tumor relapse was monitored by α-fetoprotein test and abdominal ultrasonography every 3 months and by lipiodol computed tomography every 6 months for the first year and once a year thereafter. cerebral magnetic resonance imaging, positron emission tomography, or radioisotope bone scanner was performed when necessary. Any newborn masses in the involved organ and/ or progressive elevation of α-fetoprotein levels after surgery were considered as tumor recurrence. recurrence-free survival (rFs) was defined as the cumulative time that the patient had survived without tumor relapse from the day of surgery, and recurrence after surgery was considered as the event. overall survival (os) was defined as the period from the day of surgery to patient death. survival until the end of the observation, follow-up interruption or death from a cause other than cancer relapse was considered as a censoring event.
Construction of tissue microarray (TMA).
FFpe tissue blocks were retrieved from the archives of our pathology department. Matched pairs of Hcc and the surrounding non-tumor FFpe blocks from the aforementioned patients were recruited for TMA construction. Briefly, hematoxylin and eosin stained sections from each block were reviewed and representative regions of the lesion were then selected by two senior pathologists. two tissue cores each 2.0 mm in diameter from the patient's FFpe block were punched for a total of eight tMA blocks. sections of 4 µm thickness were prepared and subjected to immnostaining of FoXM1 and pcnA. the procedure of tMA construction was technically assisted by shanghai Biochip (shanghai, china).
Immunohistochemistry (IHC).
IHc was performed as previously described with minor modifications (23) . Briefly, the sections were first deparaffinized in xylene and rehydrated through graded ethanol, then heated in boiling citrate buffer (0.01 M, pH 6.0) for 20 min in a pressure cooker for antigen retrieval. After endogenous peroxidase activity was blocked with 3% H 2 o 2 in pBs, the sections were further incubated with 10% normal goat serum for 30 min, and followed by incubation with a rabbit polyclonal anti-FoXM1 antibody (sc-502, santa cruz Biotechnology, santa cruz, cA, usA) at a dilution of 1:50 or a mouse monoclonal anti-pcnA antibody (no. 2586, cell signaling technology, Danvers, MA, USA) diluted at 1:4000 at 4˚C overnight. In the next day, the sections were washed with pBs trice and then incubated with secondary antibodies with a supervision™ universal (antimouse/rabbit) Detection reagent (Hrp) kit (D3004, shanghai long Island Biotech, china) according to manufacturer's instructions. color development was performed using liquid DAB substrate pack (HK520-yAK, Biogenex, san ramon, cA, usA) and counterstained with Mayer's hematoxylin. negative control sections were incubated with pBs instead of the primary antibody.
Semi-quantitative assessment of IHC staining. the staining results were independently evaluated by two pathologists (Dr tang and Dr Jin) without prior knowledge of the patient data. FoXM1 expression was scored as: negative (-), no staining or <10% cells with nuclear reactivity and/or weak cytoplasmic staining; positive (+), >10% cells with nuclear reactivity and/or distinct cytoplasmic staining. labeling index of PCNA (PCNA-LI) was defined as the percentage of cells with positive pcnA nuclear staining. pcnA-lI was calculated based on a minimum of 1000 total neoplastic or hepatic cells under high power fields (x400) in the representative areas. When two independent scoring of a case differed, the case was rechecked and a final consensus was achieved by the observers. If the deviation was <30% in continuous variable, the mean value was adopted as the final score, otherwise the case was re-evaluated until ultimate agreement was reached.
Statistical analysis. the differences between groups of continuous data were analyzed by t-test and categorical variables were assessed by χ 2 or Fisher's exact test. univariate analysis and survival curves were performed by Kaplan-Meier method and the difference was compared by log-rank test. cox proportional hazards model was used for multivariate analysis. All the analyses were performed with spss 13.0 software. A p-value of <0.05 was considered statistically significant.
Results

Expression of FOXM1 and its association with PCNA-LI.
FoXM1 protein on tissue sections was detected by using immunohistochemical staining with a polyclonal anti-FoXM1 antibody. The specific staining for FOXM1 was observed in the cytoplasm and/or nucleus of Hcc cells (Fig. 1A and B) , but only in cytoplasm of the non-tumorous cells (Fig. 1c) . After reviewing all stained tMA sections, one case was excluded due to lack of tumor, and positive FoXM1 expression was present in 89 of 150 cases (59.3%) (Fig. 1D) . In contrast, 36 cases (23.8%) of the 151 surrounding non-tumorous tissues showed FoXM1 positive (Fig. 1F) , indicating that FoXM1 expression was much higher in tumors than that in the non-tumorous counterparts (p<0.001; Fig. 2 ). In addition, positive staining of pcnA, a marker of proliferation, was shown mainly in the nuclei of Hcc cells (Fig. 3B and D) . pcnA labeling index was higher in Hcc tissues (38.25±27.39%) than that in the non-tumorous tissues (27.34±26.18%), difference of which is statistically significant (P<0.001). FOXM1-positive tumors were shown to have higher pcnA labeling index than that of the FoXM1-negative tumors (p<0.001; Fig. 3) .
Association of FOXM1 expression with clinicopathological parameters in HCC tissues. As shown in table I, FoXM1 expression was associated with higher AFp level (p=0.034), larger tumor size (p<0.001), multiple tumors (p=0.044), bilobar tumor involvement (p=0.020), poor tumor differentiation (p=0.042), non-cirrhotic background (p=0.011), advanced tumor stage (p<0.001), and macrovascular invasion (p<0.001) in Hcc tissues.
Association of FOXM1 expression with patient survival. the median time of the follow-up of patient was 17.8 months (ranged between 1.2-85 months). cumulative 1-, 3-and 5-year recurrence-free survivals (rFs) were 55.5, 43.4 and 38.8%, respectively, while 1-, 3-and 5-year overall survivals (os) were 81.4, 54.4 and 48.1%, respectively. tumor recurrence occurred in 77 (51.0%) patients, among whom 53 (68.8%) died of the recurrence-related death. time to the recurrence ranged from 1.0 to 60.3 months after surgery. six patients who died in less than 1 month due to surgical complications were excluded from survival analysis.
univariate analysis revealed that the rFs and os of patients with FoXM1-positive tumors were inferior to those with FoXM1-negative tumors (p<0.001; Fig. 4 and table II). Moreover, inferior rFs and os was observed in patients with younger age (p=0.026 for rFs; p=0.005 for os), higher pre-operative AFp level (p=0.004 for rFs; p=0.048 for os), larger tumor size (p<0.001 for both rFs and os), multiple tumors (p=0.002 for both rFs and os), non-cirrhotic background (p<0.001 for rFs; p=0.013 for os), macrovascular invasion (p<0.001 for both rFs and os), poor tumor differentiation (p<0.001 for both rFs and os) or advanced ptnM stage (p<0.001 for both rFs and os) (table II) .
In addition, we also performed multivariate analysis. All the significant factors in the univariate analysis were included in further multivariate analysis. the data showed that FoXM1 expression (p=0.042), macrovascular invasion (p=0.027), tumor differentiation (p=0.003), ptnM stage (p=0.049), and cirrhotic background (p=0.001) maintained independent factors to predict rFs of the patients, whereas FoXM1 expression (p=0.003), multiple tumors (p=0.023), macrovascular invasion (p<0.001), and tumor differentiation (p=0.001) were independent prognostic factors for the patient os (table III) .
Discussion
FOXM1, a typical proliferation-specific transcription factor, plays an important role in cell proliferation and organogenesis in rodents (9, 10) . recent studies have shown that FoXM1 was up-regulated in a number of human malignancies and expression of FoXM1 was involved in both tumor initiation and progression (13, 24, 25) . In the context of mouse livers, FoXM1 not only was implicated in diethylnitrosamine/ phenobarbital-induced hepatic carcinogenesis (6), but also required for proliferative expansion during Hcc development (7) . Although the pro-oncogenic function of FoXM1 in Hcc has been well substantiated by laboratory research, the expression pattern of FoXM1 and its clinical significance is not clearly understood. We found that 59.3% of the investigated Hcc samples showed positive FoXM1 expression compared with 23.8% of FoXM1-positive non-tumorous tissues, suggesting that overexpression of FoXM1 occurred in human Hcc tumors. Moreover, nuclear staining pattern of FoXM1 was observed exclusively in Hcc tissues, indicating that FoXM1 signaling was more active in tumor cells since nuclear translocation of FoXM1 is required to maximally exert its transcriptional function (11, 26) . this interpretation is further supported by our finding that FOXM1 expression in HCC was closely correlated with tumor proliferation reflected by nuclear pcnA expression. these ex vivo data suggest that --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- FoXM1 overexpression might represent a potential molecular signature of human Hcc. previous studies showed that FoXM1 expression was associated with higher histological grade, advanced tumor stage and lymph node metastasis of pulmonary squamous cell carcinoma (16) , and late stage of cervical cancer (14) . In the present study, we demonstrated a significant correlation between FoXM1 expression and aggressive clinicopathological features of Hcc, including higher AFp level, larger tumor size, multiple tumor numbers, bilobar distribution, poor tumor differentiation, macrovascular invasion and advanced stages. this association strongly suggests that FoXM1 could be further evaluated as a biomarker to identify subsets of Hcc tumors with aggressive phenotype. nevertheless, a recent study has documented discrepant data that no significant correlation was observed between FoXM1 expression and clinicopathological parameters in 58 western Hcc patients (18) . possible explanations for this discrepancy include differences in detection method for FoXM1 protein, cohort size and patient population between that and our studies.
FoXM1 expression ----------------------
In our current study of 151 Hcc patients, more than half of them developed tumor recurrence that was the predominant cause of death during the follow-up. therefore, validity of the prognostic value of FoXM1 expression could be at least helpful to identify those patients who would benefit from closer monitoring and from improved treatment strategies. previous studies demonstrated that FoXM1 expression was inversely associated with survival of Hcc patients (18) . In line with the current data, we found that expression of FoXM1 was a strong independent predictor of os for Hcc patients. More importantly, our results showed that FoXM1 could also serve as a molecular marker to predict Hcc recurrence and metastasis after liver resection, although further study needs to confirm its usefulness. This finding not only suggests that FoXM1 might help physicians to identify those patients who are at high risk of tumor recurrence, but also provides a foundation for exploring FoXM1-targeted therapy for the future care of Hcc patients.
Another interesting finding in our current study is that Hcc patients without cirrhosis had a predominant tendency for tumor recurrence. this propensity may attribute to more aggressive tumor biology manipulated by underlying molecular alterations. the interpretation is supported by the evidence that strong pre-ponderance of these patients with tumors expressing FoXM1 (table I) . However, since there were only 13 patients without cirrhosis, further investigations with more Hcc patients will be required to confirm these findings.
Hcc is a disease involving multiple and heterogeneous etiologies that exert differential effects on the molecular events that contribute to Hcc development. It is possible that a particular biomarker, which can predict prognosis of HBV-related Hcc, may not be relevant for development of HcV-related Hcc (4) . considering that our patients were dominated by HBV infection, whether FoXM1 expression can also predict risk of tumor recurrence for patients with HcV-related Hcc needs further investigation. For example, further study will clarify whether the altered expression of FoXM1 protein is due to Hcc development or HBV infection.
In summary, we demonstrated that FoXM1 was active and aberrantly expressed in human Hcc tissues and that FoXM1 overexpression was associated with proliferation and highly aggressive phenotype of Hcc. Moreover, FoXM1 expression may be a potential molecular predictor of tumor recurrence and unfavorable clinical outcome in HBV-related Hcc patients treated by hepatoectomy. the data from the current study suggest that FoXM1 may play an important role in aggressive progression of human Hcc, and that Hcc patients could substantially benefit from FoXM1-targeted therapies. In clinic, a routine evaluation of FoXM1 by immunohistochemistry may improve our insight into the prognosis and treatment of Hcc patients after liver resection. table III. the multivariate analysis for recurrence-free and overall survival of the patients (Backward test). 
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